Texas has taken legal action against Kenvue, the maker of Tylenol, and Johnson & Johnson, its former parent company, over claims that the pain reliever was wrongly marketed as safe for pregnant women. The lawsuit, filed by Texas Attorney General Ken Paxton, alleges that acetaminophen exposure in the womb can harm fetal brain development and may cause autism. This marks the first formal claim in North America linking prenatal acetaminophen use to autism, a link that most major medical organizations do not support.
The case is stirring debate, fueled in part by public statements from former President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr., who have connected Tylenol to autism without presenting new scientific evidence. Their remarks have sparked discussions about corporate responsibility and how science should inform public policy.
Kenvue responded, calling the lawsuit “baseless” and emphasizing that acetaminophen remains the safest choice for pain and fever during pregnancy when used properly. Johnson & Johnson, having spun off its consumer division in 2023, said it no longer has responsibility for Tylenol-related issues.
The U.S. Food and Drug Administration recently said it will update Tylenol’s labeling to warn that prenatal use “may be associated” with a higher risk of autism or ADHD, but made clear there is no proven cause-and-effect link. This distinction between association and causation is a key point in both the legal fight and scientific discussions.
Paxton’s lawsuit also claims Johnson & Johnson was aware of possible risks since 2014 but did not share that information. Similar lawsuits were dismissed last year in federal court after judges ruled the evidence did not meet required standards, though appeals are ongoing.
Research on acetaminophen’s effects during pregnancy is mixed. Some studies suggest a connection to developmental disorders, while others, especially those comparing siblings, find no such link when accounting for genetics and environment. Groups like the World Health Organization and the American College of Obstetricians and Gynecologists still consider acetaminophen safe when used as directed during pregnancy.
For insurance companies, Texas’s lawsuit could open the door to more lawsuits and regulatory questions. Insurers are watching closely to see if other states follow Texas’s lead and what this means for coverage of such claims, especially involving warnings and liability after corporate changes.
The Tylenol case highlights a challenge for insurers and risk managers: how to handle claims when the science is unclear and emotions run high. It sits at the crossroads of public health, regulation, and politics, showing how uncertainty itself can become a major risk.